By Fineline Cube Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval from China’s Center for Drug Evaluation (CDE) for its CD19-targeted chimeric antigen receptor (CAR)-T cell therapy, BRL-301. The therapy is set to be assessed as a treatment for acute lymphocytic leukemia (ALL).
BRL-301: A Universal Allogeneic CAR-T Formulation
BRL-301 is a groundbreaking universal allogeneic CAR-T formulation developed based on BRL Medicine’s proprietary universal cell platform, TyUCell. This innovative therapy is designed to target a range of B-cell malignant tumors, offering a potential new treatment option for patients.
Positive Signs in Investigator-Initiated Trials
To date, BRL-301 has been assessed in investigator-initiated trials, where it has demonstrated positive signs of stable quality, remarkable efficacy, and a strong safety profile. These promising results from early trials highlight the potential of BRL-301 as an effective treatment for B-cell malignancies.
Advantages of Universal CAR-T Development
The successful development of a universal CAR-T therapy like BRL-301 would offer significant advantages, particularly in terms of eased access and reduced costs compared to standard autologous CAR-T therapies. This advancement could revolutionize cancer treatment by making CAR-T cell therapies more widely available and economically feasible for a broader patient population.-Fineline Info & Tech